Trialjectory Raises $20M in Series A Funding
Summary
Trialjectory, a NYC-based, AI-powered decision-support platform for patients, health-care providers and pharma, raised $20m in a Series A funding. Scott Barclay, Managing Director of Insight Partners. The company will use the funding to expand its operations and development efforts. Led by Tzvia Bader, Co-Founder and CEO, Trialjectory is an artificial intelligence (AI)-powered decision-support platform for cancer patients to own their treatment journey by creating a personalized treatment plan that enhances physician point of care. The SaaS Optimizer platform delivers actionable insights that directly influence trial design, improve operational processes, and marketing communication strategies, while ensuring alignment with patients’ needs and expectations.